SHAREHOLDER ALERT: MPW FULC CGC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / June 1, 2023 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Medical Properties Trust, Inc. (NYSE:MPW)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/medical-properties-trust-class-action-submission-form?prid=40223&wire=1
Lead Plaintiff Deadline: June 12, 2023
Class Period: July 15, 2019 - February 22, 2023

Allegations against MPW include that: (i) the Company masked the distressed state of its tenants through sale-leaseback arrangements which were essentially round-robin transactions in that they allowed debt-saddled tenants to meet their obligations in the short-term; (ii) the Company fraudulently transferred hundreds of millions of dollars in what amounted to a bailout of financially distressed tenants; (iii) the Company concealed its fraudulent transfers with fake construction projects with purportedly high capital expenses, despite the fact that the Company entered into "triple-net leases," which meant that its tenants were obligated to pay a significant portion of expenses, such as real estate taxes, insurance, and maintenance; and (iv) as a result, the Company's public statements, including those with respect to the Pennsylvania Properties, were materially false and misleading at the time they were made.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/fulcrum-class-action-submission-form?prid=40223&wire=1
Lead Plaintiff Deadline: June 27, 2023
Class Period: March 3, 2022 - March 8, 2023

Allegations against FULC include that: (i) the preclinical data submitted in support of FTX-6058 (an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies) showed safety concerns regarding potential hematological malignancies; (ii) the foregoing safety concerns increased the likelihood that the FDA would place a clinical hold on preclinical studies of FTX-6058; (iii) accordingly, the Company had overstated FTX-6058's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Canopy Growth Corporation (NASDAQ:CGC)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/canopy-growth-class-action-submission-form?prid=40223&wire=1
Lead Plaintiff Deadline: July 24, 2023
Class Period: May 31, 2022 - May 10, 2023

Allegations against CGC include that: (1) there were material weaknesses in the Company's internal controls over accounting and financial reporting; (2) as a result, the Company improperly booked sales of its BioSteel business unit; (3) as a result, the Company's revenue was overstated; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong